{"nctId":"NCT01677910","briefTitle":"TELESTAR (Telotristat Etiprate for Somatostatin Analogue Not Adequately Controlled Carcinoid Syndrome)","startDateStruct":{"date":"2013-01-08","type":"ACTUAL"},"conditions":["Carcinoid Syndrome"],"count":135,"armGroups":[{"label":"250 mg Telotristat Etiprate","type":"EXPERIMENTAL","interventionNames":["Drug: Telotristat etiprate","Drug: Placebo-matching telotristat etiprate"]},{"label":"500 mg Telotristat Etiprate","type":"EXPERIMENTAL","interventionNames":["Drug: Telotristat etiprate","Drug: Placebo-matching telotristat etiprate"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo-matching telotristat etiprate"]},{"label":"Telotristat Etiprate Open-Label Extension","type":"EXPERIMENTAL","interventionNames":["Drug: Telotristat etiprate","Drug: Placebo-matching telotristat etiprate"]}],"interventions":[{"name":"Telotristat etiprate","otherNames":["LX1606"]},{"name":"Placebo-matching telotristat etiprate","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Histopathologically-confirmed, well-differentiated metastatic neuroendocrine tumor\n* Documented history of carcinoid syndrome and currently experiencing ≥4 bowel movements per day during the Run-in period\n* Currently receiving stable-dose somatostatin analog (SSA) therapy\n* Minimum dose of long-acting release (LAR) or depot SSA therapy\n\n  * Octreotide LAR at 30 mg every 4 weeks\n  * Lanreotide Depot at 120 mg every 4 weeks\n  * Patients who cannot tolerate SSA therapy at a level indicated above will be allowed to enter at their highest tolerated dose\n* Ability and willingness to provide written informed consent\n\nExclusion Criteria:\n\n* Presence of diarrhea attributed to any condition(s) other than carcinoid syndrome\n* Karnofsky Performance status ≤60%\n* Treatment with any tumor directed therapy, including interferon, chemotherapy, mechanistic target of rapamycin (mTOR) inhibitors \\<4 weeks prior to Screening, or hepatic embolization, radiotherapy, radiolabelled SSA, and/or tumor debulking \\<12 weeks prior to Screening\n* History of short bowel syndrome (SBS)\n* Clinically significant cardiac arrhythmia, bradycardia, tachycardia that would compromise patient safety or the outcome of the study\n* Previous exposure to telotristat etiprate","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change From Baseline in the Number of Bowel Movements (BMs) Per Day Averaged Over 12 Weeks","description":"Participants recorded the number of bowel movements per day in a daily diary. The total number of BMs per day were averaged over the 12-week period. A negative change from Baseline indicates improvement.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.623","spread":"0.8275"},{"groupId":"OG001","value":"-1.433","spread":"1.3652"},{"groupId":"OG002","value":"-1.455","spread":"1.3098"}]}]}]},{"type":"PRIMARY","title":"Number of Participants With Treatment-Emergent Adverse Events (TEAEs) in the Double-Blind Treatment Period","description":"An adverse event (AE) was defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug related. A TEAE was an AE reported after the first dose of randomized treatment on Day 1.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"39","spread":null},{"groupId":"OG001","value":"37","spread":null},{"groupId":"OG002","value":"42","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Urinary 5-hydroxyindoleacetic Acid (u5-HIAA) Levels","description":"u5-HIAA is a standard test used in clinical practice to assess neuroendocrine tumor (NET) activity and is collected as a 24-hour urine specimen. A negative change from Baseline indicates improvement.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"11.350","spread":"35.0346"},{"groupId":"OG001","value":"-40.134","spread":"84.7663"},{"groupId":"OG002","value":"-57.519","spread":"82.3273"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in the Number of Daily Cutaneous Flushing Episodes Averaged Across All Time-Points","description":"Participants recorded the number daily flushing episodes per day in a daily diary. The total number of flushing episodes per day were averaged over the 12-week period. A negative change from Baseline indicates improvement.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.164","spread":"1.1572"},{"groupId":"OG001","value":"-0.296","spread":"1.3097"},{"groupId":"OG002","value":"-0.525","spread":"1.3413"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Abdominal Pain Averaged Across All Time-Points","description":"Participants recorded abdominal pain in a daily diary. Participants evaluated the level of any abdominal pain using an 11-point numeric rating scale, where: 0=no pain to 10=worst pain ever experienced. The average daily abdominal pain was averaged over the 12-week period. A negative change from Baseline indicates improvement.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.226","spread":"1.1601"},{"groupId":"OG001","value":"-0.489","spread":"1.4423"},{"groupId":"OG002","value":"-0.333","spread":"1.1784"}]}]}]},{"type":"PRIMARY","title":"Number of Participants With TEAEs in the Open-Label Extension Period","description":"An adverse event (AE) was defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug related. A TEAE was an AE reported after the first dose of randomized treatment on Day 1.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"110","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":7,"n":45},"commonTop":["Abdominal pain","Nausea","Fatigue","Vomiting","Decreased appetite"]}}}